P
Paul G. Richardson
Researcher at Harvard University
Publications - 1631
Citations - 174221
Paul G. Richardson is an academic researcher from Harvard University. The author has contributed to research in topics: Multiple myeloma & Bortezomib. The author has an hindex of 183, co-authored 1533 publications receiving 155912 citations. Previous affiliations of Paul G. Richardson include Broomfield Hospital & Dartmouth College.
Papers
More filters
Journal ArticleDOI
A Novel Aurora-a Kinase Inhibitor MLN8237 Induces Cytotoxicity and Cell Cycle Arrest in Experimental Multiple Myeloma Models.
Gullu Gorgun,Elisabetta Calabrese,Mala Mani,Teru Hideshima,Hiroshi Ikeda,Giulia Perrone,Loredana Santo,Diana Cirstea,Simona Blotta,Paul G. Richardson,Jeffrey Ecsedy,Kenneth C. Anderson +11 more
TL;DR: The results suggest that MLN8237 represents a possible novel agent for treating MM patients and indicates that increased Aurora-A gene expression in MM may prove to be therapeutically beneficial.
Journal ArticleDOI
Molecular Analysis Of Circulating Tumor Cells Identifies Mutations That Are Distinct From Those Present In The Bone Marrow Of Patients With Multiple Myeloma
Yuji Mishima,Jens G. Lohr,Yu-Tzu Tai,Ludmila Flores,Yosra Aljawai,Jacob P. Laubach,Paul G. Richardson,Aldo M. Roccaro,Kenneth C. Anderson,Nikhil C. Munshi,Irene M. Ghobrial +10 more
TL;DR: The sequence analysis revealed that both CTCS and marrow restricted tumor cells have substantial numbers of protein-coding mutations, which suggest subclonal out growth of CTCs from one of the parent clones with acquisition of additional mutation over time outside of the bone marrow microenvironment.
Journal ArticleDOI
Long-term results of the phase II trial of the oral mTOR inhibitor everolimus (RAD001) in relapsed or refractory Waldenstrom macroglobulinemia.
Irene M. Ghobrial,Morie A. Gertz,Betsy LaPlant,John K. Camoriano,Suzanne R. Hayman,Martha Q. Lacy,Stacey Chuma,Brianna Harris,Erica N Boswell,Ranjit Banwait,Patricia Sheehy,Stephen M. Ansell,Daniel J. DeAngelo,Angela Dispenzieri,Leif Bergsagel,Craig B. Reeder,Kenneth C. Anderson,Paul G. Richardson,Steven P. Treon,Thomas E. Witzig +19 more
TL;DR: The goal was to determine the anti-tumor activity and safety of single-agent everolimus (TORC1 inhibitor) in patients with relapsed/refractory Waldenstrom macroglobulinemia.
Journal ArticleDOI
HORIZON (OP-106): An exploratory analysis of time-to-next treatment (TTNT) in patients (pts) with relapsed/refractory multiple myeloma (RRMM) who received melflufen plus dexamethasone (dex).
Maria-Victoria Mateos,Albert Oriol,Alessandra Larocca,Joan Bladé,Michele Cavo,Paula Rodriguez Otero,Xavier Leleu,John W. Hiemenz,Hani Hassoun,Cyrille Touzeau,Adrian Alegre,Agne Paner,Christopher Maisel,Amitabha Mazumder,Anastasios Raptis,Johan Harmenberg,Stojan Zavisic,Sara Thuresson,Oskar Öhman,Paul G. Richardson +19 more
TL;DR: Melflufen + dex showed efficacy and a manageable safety profile in pts with dex, and a novel peptide-drug conjugate that rapidly delivers a cytotoxic payload into tumor cells was presented.